AwardJun 26, 2026, 06:08 AM
eXoZymes Awarded $2M NIH Grant for Cannabinoid Drug Discovery
AI Summary
eXoZymes Inc. announced it has been awarded a $2,028,518 Phase IIB Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This significant non-dilutive funding will be used to advance cannabinoid analogs for drug discovery, expanding the company's portfolio of proprietary molecules and potential future pharmaceutical assets. The award brings eXoZymes' total non-dilutive funding to nearly $20 million and marks the second biosolution in its pipeline advancing towards partnership and commercialization, with work expected to begin on July 1, 2026.
Key Highlights
- eXoZymes Inc. received a $2,028,518 Phase IIB SBIR grant from the NIH.
- The grant will advance cannabinoid analogs for drug discovery.
- Total non-dilutive funding awarded to eXoZymes now stands at almost $20 million.
- NIH-backed work is expected to commence on July 1, 2026.
- The grant will support advanced development of cannabinoid cyclase enzyme expression systems.
- It will also enable strategic expansion of the range of cannabinoid analogs produced.
- Preclinical evaluation of the company's existing cannabinoid library is a key objective.
Price Impact
More from EXOZ